Program
osimertinib
Also written as “Osimertinib”, “AZD9291” and “AZD9291 tablet dosing”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Neoplasms · Renal Insufficiency · Carcinoma, led by 3 companies.
Drug pageOsimertinib: every studyAll 130 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 3914 open or running | phase 4since Feb 20, 2019 | Feb 25, 2013 | Feb 22, 2027phase 3 · NCT05629234 |
| Eli Lillyits history only | 21 open or running | phase 3since Apr 3, 2015 | Apr 3, 2015 | none ahead |
| Novartis | 10 open or running | phase 3since Mar 22, 2021 | Mar 22, 2021 | none ahead |
Also a collaborator on its studies: Parexel, TigerMed and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2021First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04816214 · 6 enrolled · Japan, Korea, Republic of, Singapore
TargetBeta
“A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
The one study Novartis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04816214Carcinoma, Non-Small-Cell Lung · Japan, Korea, Republic of, Singapore | 3 | Terminated | Dec 27, 2022 | 6 |
How it is read
Names in the registry
- “Osimertinib”, 14 entries
- “AZD9291”, 14 entries
- “AZD9291 tablet dosing”, 5 entries
- “AZD9291 Dosing”, 2 entries
- “Part A - AZD9291 in combination with AZD6094”, 1 entry
Codes read as this program: AZD9291.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 28 studies
- Lung Neoplasms, 5 studies
- Neoplasms, 4 studies
- Renal Insufficiency, 1 study
- Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.